The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Alongside her husband, Bob Duggan, Maky Zanganeh has guided cancer drug developer Summit Therapeutics to reach staggering new ...

Merck faces a looming challenge with the 2028 patent expiration of Keytruda, but it’s not sitting around twiddling test tubes ...

Barron’s has long favored dividend-paying stocks for those seeking income. But bonds now deserve a hard look because they are ...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

SCHD’s Track Record and Recent Dividend Cut The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) is a favorite among ...